The Company’s therapeutic focus is on onology, neurology and immunology and the development of orphan drugs. Ergomed Plc manages clinical development from Phase I through to late phase programs. The Company operates in two segments: The services business and the co-development business. The clinical development services offered by the Company include study management, site management, study physician support, safety services, regulatory and quality management, clinical data management and biostatistics, and medical writing. It has planned, managed, monitored, and reported clinical trials with a range of technologies that include small molecule drugs, monoclonal antibodies, tri-functional antibodies, soluble receptors, cancer vaccines and immunotherapy, radioactive agents, and photodynamic therapies. The Company also has co-development deals with other companies.
Type
Public
HQ
Guildford, GB
Employees
150 (est)

Ergomed Locations

Guildford, GB

Ergomed Metrics

Ergomed Summary

Market capitalization

£44.5 M

Closing share price

£1.44

Ergomed Financials

FY, 2013FY, 2014FY, 2015

Revenue

£15.1 M£21.2 M£30.2 M

Revenue growth, %

39.7%42.7%

Cost of sales

£10.1 M£15.4 M£21.8 M

Gross profit

£5 M£5.77 M£8.37 M

Gross profit Margin, %

33.0%27.3%27.7%

Operating expense total

£3.23 M£4.99 M£6.3 M

Ergomed Market Value History

Ergomed Company Life

You may also be interested in